share_log

Goldman Sachs Initiates Coverage On Rocket Pharmaceuticals With Neutral Rating, Announces Price Target of $39

Moomoo 24/7 ·  Apr 2 07:07

Goldman Sachs analyst Richard Law initiates coverage on Rocket Pharmaceuticals (NASDAQ:RCKT) with a Neutral rating and announces Price Target of $39.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment